Fletcher Robert S sold $1.4M of SYK

Fletcher Robert S (VP, Chief Legal Officer) sold 4,544 shares of STRYKER CORP (SYK) at an average of $306.87 ($304.22–$310.22, $1.39M total) across 6 trades on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fletcher Robert S
Published May 29, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Bearish
medium confidence
Mentioned
$SYK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings and may influence short‑term sentiment.

02

Market read

A C‑suite insider sale of $1.4M is a modest but noteworthy event for traders monitoring insider activity.

03

What to watch

Potential tax planning or diversification motives; the 10b5‑1 plan pre‑arranged nature may reduce negative signal.

Relevance 5/10Novelty 6/10Timing: after-hours filing on 2026-05-29

Background

Form 4 filing discloses insider transactions required by SEC; such filings are primary sources of new information.

Company-level read

Ticker impact

$SYKBearishMedium confidence
Context

VP Chief Legal Officer Fletcher Robert S sold 4,544 shares for $1.39M via a 10b5-1 plan, reducing his stake to 10,582 shares.

Expected impact

likely downward pressure as market prices in the insider sell

Evidence & confidence

The sale size (~$1.4M) is modest for a large cap, but the insider is a C‑suite officer; such sales often trigger short‑term selling pressure.

Market effects

Minimal impact on the broader medical devices sector; the sale is company‑specific.

U.S. market only; no regional ripple.

Low; limited to SYK investors.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Fletcher Robert S

    VP, Chief Legal Officer of Stryker Corp.

  • Stryker Corp.

    Medical device manufacturer (ticker SYK).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

$SYKHighAI 8/10

Stifel cuts Stryker stock price target on weak quarter, guidance

Stifel reduced its price target for Stryker (NYSE:SYK) to $325 from $330, maintaining a Buy rating after the company's Q3 results missed expectations. Stryker reported Q3 sales of $6.52B, below estimates, and lowered its full-year organic sales growth guidance to 6.5-7.0%. Multiple analysts have revised earnings downward, citing execution issues and market slowdowns.

$SYKHighAI 8/10

Stryker Earnings Call Balances Growth With Caution

Stryker Corp (SYK) reported Q3 earnings with 7.7% organic sales growth, 10.3% adjusted EPS increase to $3.52, and margin expansion. Growth was led by MedSurg and Neurotechnology, while Orthopaedics faced challenges. Management highlighted strong capital demand, innovation pipeline, and M&A activity, but acknowledged hip and knee market slowdowns and execution issues.